A
GTBP icon

Alongside’s GT Biopharma GTBP Stock Holding History

Alongside’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2,560
Closed -$31.3K – 278
2026
Q2 		$31.3K Buy
+2,560
New +$26K 0.01% 190

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Alongside's GTBP Position: Q3 2026 in Review

Alongside sold out of GT Biopharma (GTBP) in Q3 2026, closing a stake of 2,560 shares — an estimated $31.3K sold.

Alongside first reported a position in GTBP in Q2 2026 and held it in 1 quarter. The position peaked at $31.3K in Q2 2026. 22 funds tracked by Wall St. Rank hold GTBP as of Q3 2026.

  • Alongside reported no remaining GT Biopharma position as of Q3 2026 after selling out during the quarter.
  • Alongside sold 2,560 GT Biopharma shares in Q3 2026, an estimated $31.3K.
  • Alongside first reported a position in GT Biopharma in Q2 2026 and held it in 1 quarter.
  • Alongside's GT Biopharma position peaked at $31.3K in Q2 2026.
  • 22 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2026.

Based on Alongside's 13F filing for Q3 2026, filed 13 Nov 2026.